Delilah Alvarado
Reporter | LinkedInDelilah is a reporter for BioPharma Dive. Before Industry Dive she covered business tech and startup news and has reported on social issues, politics and culture. She has a B.S. from Texas State University and is obsessed with dogs and horror films. She can also be reached on Signal at @DelilahAlvarado.70.
552 articles by Delilah Alvarado
-
AbCellera, Vertex partner on next-gen T-cell engagers
July 29, 2026 -
GSK prepares for patent cliff with $2.5B cost-cutting plan
July 28, 2026 -
Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug
July 27, 2026 -
Jasper gets a lifeline in merger with immune drugmaker Kira
July 17, 2026 -
Celcuity gains FDA approval for closely watched breast cancer drug
July 15, 2026 -
Draig bags another $65M to speed testing of brain drugs
July 14, 2026 -
GSK, Hansoh ADC extends survival in lung cancer study
July 10, 2026 -
Oberland pours up to $400M into MeiraGTx eye gene therapies
July 7, 2026 -
Vera Therapeutics wins FDA nod for closely watched kidney disease drug
July 7, 2026 -
Novartis to acquire ADC developer in a deal worth up to $1.5B
July 6, 2026 -
Viridian may have edge over Amgen in eye drug showdown, analysts argue
June 30, 2026 -
Ionis, with new FDA nod, hits a ‘commercial inflection point’
June 24, 2026 -
Investors pour $115M into RQ Bio in search of a preventive flu drug
June 24, 2026 -
Pfizer drug acquired in Seagen deal disappoints in lung cancer study
June 23, 2026 -
Moderna flu vaccine wins unanimous support from FDA panel
June 18, 2026 -
FDA staff scrutinizes evidence supporting Moderna’s flu vaccine
June 16, 2026 -
J&J multiple myeloma drug gains edge in earlier stage disease
June 15, 2026 -
Ethyreal starts up with $101M and takes aim at a pair of immune diseases
June 10, 2026 -
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
June 9, 2026 -
An ADC specialist sinks on safety concerns for blood cancer drug
June 4, 2026 -
Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
June 2, 2026 -
ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer
June 2, 2026 -
At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
May 29, 2026 -
FDA delays decision on AstraZeneca breast cancer pill
May 27, 2026 -
Lilly dives into vaccine research with 3 biotech buyouts
May 26, 2026
